Maclean F. Michael's most recent trade in Verve Therapeutics Inc was a trade of 42,200 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Verve Therapeutics Inc | Michael F. Maclean | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 42,200 | 42,200 | - | - | Stock Option (right to buy) | |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.06 per share. | 20 Mar 2025 | 7,935 | 96,720 | - | 31.1 | 246,425 | Common Stock |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.59 per share. | 21 Jan 2025 | 1,665 | 104,655 | - | 28.6 | 47,608 | Common Stock |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.59 per share. | 21 Jan 2025 | 1,622 | 106,320 | - | 28.6 | 46,378 | Common Stock |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 25,000 | 107,942 | - | 0 | Common Stock | |
| Avidity Biosciences Inc | Michael Maclean F. | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.66 per share. | 18 Dec 2024 | 11,151 | 82,942 | - | 32.7 | 364,192 | Common Stock |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Nov 2024 | 65,182 | 0 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 45.33 per share. | 06 Nov 2024 | 65,182 | 94,093 | - | 45.3 | 2,954,954 | Common Stock |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.82 per share. | 06 Nov 2024 | 65,182 | 159,275 | - | 8.8 | 574,905 | Common Stock |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 46.22 per share. | 06 Nov 2024 | 27,262 | 94,093 | - | 46.2 | 1,260,017 | Common Stock |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 45.33 per share. | 06 Nov 2024 | 13,875 | 94,093 | - | 45.3 | 629,008 | Common Stock |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Nov 2024 | 13,875 | 60,125 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.57 per share. | 06 Nov 2024 | 13,875 | 107,968 | - | 6.6 | 91,159 | Common Stock |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2024 | 25,000 | 121,355 | - | 0 | Common Stock | |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2024 | 25,000 | 107,865 | - | 0 | Common Stock | |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 44.00 per share. | 19 Sep 2024 | 11,510 | 96,355 | - | 44 | 506,440 | Common Stock |
| Verve Therapeutics Inc | Michael F. Maclean | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 136,139 | 136,139 | - | - | Stock Option (right to buy) | |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 25,000 | 69,093 | - | 0 | Common Stock | |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 25,000 | 82,865 | - | 0 | Common Stock | |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 39.13 per share. | 17 Jun 2024 | 11,228 | 57,865 | - | 39.1 | 439,345 | Common Stock |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.82 per share. | 12 Jun 2024 | 104,245 | 148,338 | - | 8.8 | 919,441 | Common Stock |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.72 per share. | 12 Jun 2024 | 104,245 | 44,093 | - | 35.7 | 3,723,141 | Common Stock |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 104,245 | 65,182 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.82 per share. | 14 May 2024 | 75,000 | 119,093 | - | 8.8 | 661,500 | Common Stock |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.28 per share. | 14 May 2024 | 75,000 | 44,093 | - | 28.3 | 2,121,045 | Common Stock |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 75,000 | 169,427 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 40,000 | 244,427 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 24.52 per share. | 13 Mar 2024 | 40,000 | 44,093 | - | 24.5 | 980,760 | Common Stock |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.82 per share. | 13 Mar 2024 | 40,000 | 84,093 | - | 8.8 | 352,800 | Common Stock |
| Avidity Biosciences Inc | F. Michael Maclean | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2024 | 106,000 | 106,000 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2024 | 22,500 | 27,209 | - | 0 | Common Stock | |
| Avidity Biosciences Inc | Maclean F. Michael | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 10.13 per share. | 20 Jan 2024 | 1,616 | 16,884 | - | 10.1 | 16,370 | Common Stock |
| Verve Therapeutics Inc | Michael F. Maclean | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 26,642 | 26,642 | - | - | Stock Option (right to buy) | |
| Verve Therapeutics Inc | Michael F. Maclean | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 7,000 | 7,000 | - | - | Stock Option (right to buy) | |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 148,000 | 148,000 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 18,500 | 21,852 | - | 0 | Common Stock | |
| Verve Therapeutics Inc | Michael F. Maclean | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 15,500 | 15,500 | - | - | Stock Option (right to buy) | |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 131,250 | 131,250 | - | - | Stock Option (Right to Buy) | |
| Verve Therapeutics Inc | Michael F. Maclean | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 47,664 | 47,664 | - | - | Stock Option (right to buy) | |
| Avidity Biosciences Inc | Michael F. Maclean | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 92,000 | 92,000 | - | - | Stock Option (Right to Buy) |